Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News OncoSec Medical Inc ONCSQ

Healthcare Biotechnology
OncoSec Medical Incorporated is a late-stage immuno-oncology company. The Company is focused on designing, developing and commercializing intra-tumoral DNA-based therapeutics delivered by electroporation (EP) to stimulate and augment anti-tumor immune responses for the treatment of cancers. Its core technology, ImmunoPulse, is a drug-device therapeutic modality platform comprised of an OncoSec... see more

Recent & Breaking News (GREY:ONCSQ)

OncoSec to Present at Scientific and Investment Conferences in March

PR Newswire March 7, 2017

OncoSec to Host Second Quarter Financial Conference Call on March 16, 2017

PR Newswire March 2, 2017

OncoSec Granted FDA Fast Track Designation for ImmunoPulse® IL-12 for the Treatment of Metastatic Melanoma Following Progression on Pembrolizumab or Nivolumab

PR Newswire February 27, 2017

OncoSec to Host KOL Event Focused on New ASCO-SITC Melanoma Data and Clinical Strategy on Tuesday, February 28 in New York City

PR Newswire February 24, 2017

OncoSec Announces Positive Phase II Data Demonstrating Company's ImmunoPulse® IL-12 in Combination with Pembrolizumab Increased Response Rates in Anti-PD-1 Non-Responder Melanoma Patients

PR Newswire February 23, 2017

OncoSec to Present New Clinical Data from Phase 2 Combination Study at ASCO-SITC Clinical Immuno-Oncology Symposium and Corporate Updates at Two Investment Conferences in February

PR Newswire February 8, 2017

OncoSec to Present at NobleCon13

PR Newswire January 26, 2017

OncoSec to Present at Investment Conferences in January

PR Newswire January 3, 2017

OncoSec Announces First Quarter Financial Results for Fiscal Year 2017

PR Newswire December 8, 2016

OncoSec to Present at the 9th Annual LD Micro Main Event

PR Newswire December 1, 2016

OncoSec Announces Key Corporate Initiatives at Inaugural Investor & Analyst Day on November 17, 2016

PR Newswire November 17, 2016

OncoSec to Host First Quarter Financial Results Conference Call on December 8, 2016

PR Newswire November 15, 2016

OncoSec Presents Positive Interim Response Data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2016

PR Newswire November 11, 2016

OncoSec Announces Positive Interim Response Data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2016

PR Newswire November 8, 2016

OncoSec to Present at Scientific and Investment Conferences and to Host Inaugural Investor and Analyst Day in November

PR Newswire November 1, 2016

OncoSec to Host Investor & Analyst Day on November 17, 2016 Spotlighting Industry-Leading Intratumoral Immunotherapy Pipeline and Next Generation Research and Device Development

PR Newswire October 18, 2016

OncoSec Sees A Wider Loss Than Expected In Q4 While ImmunoPulse Trial Remains On Track

Benzinga.com  October 14, 2016

OncoSec Announces Fourth Quarter and Year End Results for Fiscal Year 2016

PR Newswire October 13, 2016

OncoSec Announces Acceptance of Late Breaking Abstract at Upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting 2016

PR Newswire October 13, 2016

OncoSec to Present at Scientific and Investment Conferences in October

PR Newswire October 10, 2016